Structure-activity relationships of the cycloalkanol ethylamine scaffold: Discovery of selective norepinephrine reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 4038-4049

  Mahaney, Paige E ^a   Gavrin, Lori K ^a   Trybulski, Eugene J ^a   Stack, Gary P ^a   Vu, An T ^a   Cohn, Stephen T ^a,c   Ye, Fei ^a   Belardi, Justin K ^a   Santilli, Arthur A ^a   Sabatucci, Joseph P ^a   Leiter, Jennifer ^a   Johnston, Grace H ^a,d   Bray, Jenifer A ^a   Burroughs, Kevin D ^a,d   Cosmi, Scott A ^a   Leventhal, Liza ^a,e   Koury, Elizabeth J ^a   Zhang, Yingru ^a,f   Mugford, Cheryl A ^a   Ho, Douglas M ^b,g   Rosenzweig Lipson, Sharon J ^a   Platt, Brian ^a   Smith, Valerie A ^a   Deecher, Darlene C ^a   more..

^a PFIZER INC   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^d Neotropix Inc   (United States)

^e EnVivo Pharmaceuticals   (United States)

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^g HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DESIPRAMINE; DOPAMINE TRANSPORTER; DULOXETINE; MILNACIPRAN; NISOXETINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN TRANSPORTER; VENLAFAXINE; WAY 256805; WY 46824;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; MOUSE; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CYCLOHEXANOLS; ETHYLAMINES; FEMALE; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NOREPINEPHRINE; PAIN; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS;

EID: 46849111428     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8002262     Document Type: Article

References (49)

1. (a) Devilbiss, D. M.; Page, M. E.; Waterhouse, B. D. Locus coeruleus regulates sensory encoding by neurons and networks in waking animals. J. Neurosci. 2006, 26, 9860-9872.
2. (b) Aston-Jones, G.; Cohen, J. D. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J. Comp. Neurol. 2005, 493, 99-110.
3. (c) Valentino, R. J.; Van Bockstaele, E. J. Functional interactions between stress neuromediators and the locus coeruleus-norepinephrine system. Tech. Behav. Neurosci. 2005, 15, 465-486.
4. (d) Cirelli, C.; Tononi, G. Locus coeruleus control of state-dependent gene expression. J. Neurosci. 2004, 24, 5410-5419.
5. (e) Miyawaki, T.; Kawamura, H.; Komatsu, K.; Yasugi, T. Chemical stimulation of the locus coeruleus: inhibitory effects on hemodynamics and renal sympathetic nerve activity. Brain Res. 1991, 568, 101-108.
6. Sarvey, J. Protein synthesis in long-term potentiation and norepinephrine-induced long-lasting potentiation in hippocampus. Neurol. Neurobiol. 1998, 35, 329-353 and references therein.
7. (a) Fricchione, G.; Stefano, G. B. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med. Sci. Monit. 2005, 11, MS54-MS65.
8. (b) Kalivas, P. W.; Volkow, N.; Seamans, J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 2005, 45, 647-650.
9. (c) Pochon, J. B.; Levy, R.; Fossati, P.; Lehericy, S.; Poline, J. B.; Pillon, B.; Le Bihan, D.; Dubois, B. The neural system that bridges reward and cognition in humans: an fMRI study. Proc. Nat. Acad. Sci. U.S.A. 2002, 99, 5669-5674.
10. (a) Kumar, V. N. Interrelation between thermoregulation and sleep regulation. Proc. Natl. Acad. Sci., India, Sect. B 2003, 69, 507-524.
11. (b) Riedel, W.; Dorward, P. K.; Korner, P. I. Central adrenoceptors modify hypothalamic thermoregulatory patterns of autonomic activity in conscious rabbits. Auton. Neurosci. 1981, 3, 525-533.
12. (c) Lahti, H.; Pyornila, A.; Hissa, R. The influence of 6-OHDA on hypothermia produced by intrahypothalamically-injected carbachol in the pigeon. Experientia 1980, 36, 1188.
13. (a) Michel, M. C.; Ruhe, H. G.; de Groot, A. A.; Castro, R.; Oelke, M. Tolerability of amine uptake inhibitors in urologic diseases. Curr. Drug Safety 2006, 1, 73-85.
14. (b) Michel, M. C.; Oelke, M. Duloxetine in the treatment of stress urinary incontinence. Women's Health 2005, 1, 345-348.
15. (c) Osborne, K. L.; Davis, S. M. Duloxetine in the treatment of stress urinary incontinence. J. Pharm. Technol. 2005, 21, 337-340.
16. (d) McCormack, P. L.; Keating, G. M. Duloxetine: in stress urinary incontinence. Drugs 2004, 64, 2567-2573.
17. (a) Preskorn, S. H.; Ross, R. Other Antidepressants. Handb. Exp. Pharmacol. 2004, 157, 263-324.
18. (b) Carminati, G. G.i.; Deriaz, N.; Bertschy, G. Low dose vanlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 312-315.
19. (a) Arnold, L. M.; Lu, Y.; Crofford, L. J.; Wohlreich, M.; Detke, M. J.; Iyengar, S.; Goldstein, D. J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004, 50, 2974-2984.
20. (b) Arnold, L. M.; Rosen, A.; Pritchett, Y. L.; D'Souza, D. N.; Goldstein, D. J.; Iyengar, S.; Wernicke, J. F. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119, 5-15.
21. (c) Sayar, K.; Aksu, G.; Ak, I.; Tosun, M. Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. 2003, 37, 1561-1565.
22. Bymaster, F. P.; Katner, J. S.; Nelson, D. J.; Hemrick-Luecke, S. K.; Threlkeld, P. J.; Heiligenstein, J. H.; Morin, S. M.; Gehlert, D. R.; Perry, K. W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: a potential mechanism for efficacy in attention hyperactivity disorder. Neuropsychopharmacology 2002, 27, 699-711.
23. (a) Krell, H. V.; Leuchter, A. F.; Cook, I. A.; Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46, 379-384.
24. (b) Berigan, T. Use of atomoxetine adjunctively in fybromyalgia syndrome. Can. J. Psychiatry 2004, 49, 499-500.
25. Yardley, J. P.; Husbands, G. E. M.; Stack, Gary, Butch, J.; Bicksler, J.; Moyer, J. A.; Muth, E. A.; Andree, T.; Fletcher, H.; James, M. N. G.; Sielecki, A. R. 2-Phenyl-2-(1-hydroxylcycloalkyl)ethylamine derivatives: synthesis and antidepressant activity. J. Med. Chem. 1990, 33, 2899-2905.
26. Mason, J. N.; Deecher, D. C.; Richmond, R. L.; Stack, G.; Mahaney, P. E.; Trybulski, E. J.; Winneker, R. C.; Blakely, R. D. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J. Pharmacol. Exp. Ther. 2007, 323, 720-729.
27. (a) Reith, M. E. A.; Meisler, B. E.; Sershen, H.; Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 1986, 35, 1123-1129.
28. 3H]Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 1989, 251, 131-141.
29. (a) Steru, L.; Chermat, R.; Thierry, B.; Simon, P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85, 367-370.
30. (b) Porsolt, R. D.; Chermat, R.; Lenegre, A.; Avril, I.; Janvier, S.; Steru, L. Use of the automated tail suspension test for the primary screening of psychotropic agents. Arch. Int. Pharmacodyn. Ther. 1987, 288, 11-30.
31. (c) Teste, J. F.; Martin, I.; Rinjard, P. Electrotherapy in mice: dopaminergic and noradrenergic effects in the tail suspension test. Fundam. Clin. Pharmacol. 1990, 4, 39-47.
32. (d) Cryan, J. F.; Mombereau, C.; Vassout, A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29, 571-625.
33. Ripoll, N.; David, J. P.; Dailly, E.; Hascoet, M.; Bourin, M. Antidepressant-like effects in various mice strains in the tail suspension test. Behav. Brain Res. 2003, 143, 193-200.
34. Siegmund, E.; Cadmus, R.; Lu, G. A method for evaluating both non-narcotic and narcotic analgesics. Proc. Soc. Exp. Biol. Med. 1957, 95, 279-731.
35. (a) Zhou, M.; Gebhart, G. F. Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticualris gigantocellularis and gigantocellularis pars alpha in the rat. Brain Res. 1991, 550, 35-48.
36. (b) Holden, J. E.; Schwartz, E. J.; Proudfit, H. K. Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha 1-and alpha2-adrenoceptors. Neuroscience 1999, 91, 979-990.
37. (a) Gebhart, G. Modulatory Effects of Descending Systems on Spinal Dorsal Horn Neurons. In Spinal Afferent Processing; Yaksh, T. L., Ed.; Plenum: New York, 1986; pp 391-416.
38. (b) Fields, H. L.; Heinricher, M. M.; Mason, P. Neurotransmitters in nociceptive modulatory circuits. Annu. Rev. Neurosci. 1991, 14, 219-245.
39. (c) Fields, H. L.; Basbaum, A. Central Nervous System Mechanisms of Pain Modulation. In Textbook of Pain; Wall, P. D., Melzack, R., Eds.; Churchill Livingstone: London, 1999; pp 309-329.
40. (d) Millan, M. J. Descending control of pain. Prog. Neurobiol. 2002, 66, 355-474.
41. Leventhal, L.; Smith, V.; Hornby, G.; Andree, T. H.; Brandt, M. R.; Rogers, K. E. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. J. Pharmacol. Exp. Ther. 2007, 320, 1178-1186.
42. (a) Berendsen, H. H.; Weekers, A. H.; Kloosterboer, H. J. Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats. Eur. J. Pharmacol. 2001, 419, 47-54.
43. (b) Sipe, K.; Leventhal, L.; Burroughs, K.; Cosmi, S.; Johnston, G. H.; Deecher, D. C. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res. 2004, 1028, 191-202.
44. (a) Deecher, D. C.; Alfinito, P.; Leventhal, L.; Johnston, G. H.; Cosmi, S.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007, 148, 1376-1383.
45. (b) Maswood, N.; Alfinito, P. D.; Cosmi, S.; Leventhal, L.; Johnston, G. H.; Deecher, D. C. Evalulation of the selective serotonin reuptake inhibitor, fluoxetine, in ovariectomized (OVX) rat models of temperature regulation. Neuroendocrinology 2006, 85, 330-338.
46. Pawlyk, A. C.; Cosmi, S.; Alfinito, P. D.; Maswood, N.; Deecher, D. C. Effects of the 5-HT2A antagonist mirtazapine in rat models of thermoregulation. Brain Res. 2006, 1123, 135-144.
47. Pacholczyk, T.; Blakely, R. D.; Amara, S. G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991, 350, 350-354.
48. Ramamoorthy, J. D.; Ramamoorthy, S.; Papapetropoulos, A.; Catravas, J. D.; Leibach, F. H.; Ganapathy, V. Cyclic AMP-independent up-regulation of the human serotonin transporter by staurosporine in choriocarcinoma cells. J. Biol. Chem. 1995, 270, 17189-17195.
49. 3H]GBR 12,935 binding. Mol. Pharmacol. 1994, 45, 125-35.